Track topics on Twitter Track topics that are important to you
21st August 2017, Oxford Oxford Genetics, a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery, has announced a 7.5 million investment into its operations in the US and the UK by Mercia Technologies PLC, an existing investor, and Invesco Perpetual. This investment will fund a new office in Boston, US and a...
Original Article: Oxford Genetics Secures ??7.5 Million InvestmentNEXT ARTICLE
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...